Mietani, Kazuhito
Hasegawa-Moriyama, Maiko
Yagi, Koichi
Inoue, Reo
Ogata, Toru
Shimojo, Nobutake
Seto, Yasuyuki
Uchida, Kanji
Sumitani, Masahiko
Funding for this research was provided by:
Japanese Society for Promotion of Science (19H03749)
Science Research Grant for research on chronic pain (H26-Cancer-060)
Article History
Received: 1 July 2022
Accepted: 30 September 2022
First Online: 12 October 2022
Competing interests
: The department to which M.H-M. belongs is supported by Nippon Zoki Pharmaceutical Co., Ltd. (Osaka, Japan), Shionogi Co., Ltd. (Osaka, Japan), Heartfelt Co., Ltd. (Kumamoto, Japan) and Aiwa Hospital (Nagano, Japan). K.U. has collaborative research agreement accompanied with research funding with Nipro Corporation (Osaka, Japan) and Nihon Kohden Corporation (Tokyo, Japan) on topics unrelated to the present study. Other authors K.M., K.Y., R.I., T.O., N.S., Y.S., and M.S. declare that they have no competing interest to report.